AF3485 is a human mPGES-1 inhibitor with demonstrated anti-tumor activity in vitro and in vivo; it suppresses tumor-associated angiogenesis by reducing PGE2 production, inhibiting EGFR signaling, and downregulating VEGF and FGF-2 expression; it reduces tumor growth in mice bearing human A431 xenografts upon subchronic administration.